Drug-Eluting Embolic Bead
Phase 3Small molecule
Drug-Eluting Embolic Bead is one of 34 small molecule programs targeting Colorectal Cancer. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
949 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Eylea
RegeneronPreclinical
Drug-Eluting Embolic Bead
TTehran University of Medical Sciences
Phase 3
Xylocaine
MMEDRx USA, Inc.
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Vascepa
AAmarin Pharma Inc.
Preclinical
Andriol
AAuxilium
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Ketalar
AAultman Health Foundation
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Drug-Eluting Embolic Bead. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details